This portfolio stock has just pulled Q1 2020 guidance, saying revenue will be roughly 35% to 45% below the low end of its prior revenue guidance ($47 million) due to global disruptions from COVID-19.
Read More
From Cabot Top Ten Trader
All in all, the evidence has improved somewhat over the past week, based on the positive new-low divergence, the continued pessimism and the initial breadth of the rally. Consider it a good first step. But it’s still best to positioned...
Read More
Some Short-Term Signs of Spring
We can’t remember a time when the news flow came as fast and furious as it has in recent weeks, from state-wide shutdowns to big market swings to stimulus packages to Federal Reserve actions. That’s why it’s good to a..
Read More
The past week has seen the market rocket higher on hopes for a massive $2 trillion economic stimulus plan that would try to help consumers and businesses get through the tunnel of productivity and financial devastation that this pandemic has created.
Read More
In such an environment it’s easy to assume the worst and miss the flipside of the equation – great companies trading at prices that just a month ago we would have considered incredible. Market volatility and uncertainty are creating great opportunities.
Read More
This biotech is working on a coronavirus vaccine that looks promising.
Read More
The market doesn’t know how long this will last. And that’s why it hasn’t been able to find a bottom. But there has been some very encouraging news in the past week.
Read More
The economy has fallen into a recession. The official economic statistics are not at our doorsteps yet – two quarters of falling GDP – but it’s fairly obvious that American business has gone into hibernation for at least a few months.
Read More
Biotechs around the world are scrambling to find a coronavirus vaccine. These three small-cap biotech stocks appear to be among the closest.
Read More
As the coronavirus rages and stocks continue to fall, here are 16 positives - market-related and otherwise - to celebrate as we wait for a better day.
Read More
The market is strong, our portfolio is full, and the prospects for the months ahead look good. Thus I continue to recommend that you be heavily invested in stocks that help you meet your investing goals.
Read More
Stock Recommendation Tracker
The Stock Recommendation Tracker is a table that features all of the current recommendations in all of our portfolios. It’s a quick way for you to see what stocks are currently in our portfolios and will highlight new additions or any to...
Read More
Stock Recommendation Tracker
The Stock Recommendation Tracker is a table that features all of the current recommendations in all of our portfolios. It’s a quick way for you to see what stocks are currently in our portfolios and will highlight new additions or any to...
Read More
This biotech is forecasted to grow 16.10% next year. And four analysts have recently increased their EPS estimates for the company.
Read More
As financial markets begin to thaw, global leaders build consensus on how to address this pandemic, options of potential interim treatments for Covid-19 surface and the framework of economic relief starts to firm up (even though it won’t be enough), the stock market be...
Read More
Stock Name
Market Cap
Price
Investment Type
BellRing Brands (BRBR)
$600 million
15.23
Growth – Packaged Foods
BlackLine (BL)
$2.76 billion
48.98
Rapid Growth – Accounting Software
Kroger (KR)
$26.9 billion
34.19
Steady, Slow Growth – Grocery Store
Survey Monkey (SVMK)
$1.5 billion
10.67
Rapid Growth – Survey Software
Sunnova (NOVA)
$624 million
7.43
Growth – Solar Panels & Storage
Searching for Turnip Shoots on a Scorched I..
Read More
Remain defensive. There are certainly indications that a countertrend rally could start at any time, so we’re not anxious to raise more cash, but we’re sticking with the trend, which remains down. In the Model Portfolio, we have no changes tonight—we’re holding four stocks...
Read More
Our Emerging Markets Timer as found support in recent weeks, but that hasn’t been enough to produce a new buy signal.
Read More
What are the investing implications of a best-, base- and worst-case scenario for Americans amid this global pandemic? Let's break it down.
Read More
Analyst note: With all that’s going on in the market and all the disruptions we’re dealing with as families working from home we’re altering the editorial schedule and format of Cabot Early Opportunities for a short period of time. The immediate goal is focus...
Read More
